Information in this table can be sorted by Author, Title or Journal. Click on column headings to sort.
Author |
Title | Journal | Abstract | ||||
|---|---|---|---|---|---|---|---|
| Akatsu T, Murakami T, Nishikawa M, et al. | Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. | Biochem Biophys Res Comm. 1998;250:229-234. | View PubMed Abstract | ||||
| Anderson DM, Maraskovsky E, Billingsley WL, et al. | A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. | Nature. 1997;390:175-179. | View PubMed Abstract | ||||
| Atkins GJ, Bouralexis S, Haynes DR, et al. | Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. | Bone. 2001;28:370-377. | View PubMed Abstract | ||||
| Barkin R. | Perception, assessment, treatment, and management of pain in the elderly. | Clinics in Geriatric Medicine. Philadelphia, PA: W.B. Saunders Company; 2005. | View PubMed Abstract | ||||
| Baum M, Budzar AU, Cuzick J, et al. | Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. | Lancet. 2002;359:2131-2139. | View PubMed Abstract | ||||
| Bekker PJ, Holloway D, Nakanishi A, et al. | The effect of a single dose of osteoprotegerin in postmenopausal women. | J Bone Min Res. 2001;16:348-360. | View PubMed Abstract | ||||
| Body JJ, Greipp P, Coleman RE, et al. | A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. | Cancer. 2003;97(3 suppl):887-892. | View PubMed Abstract | ||||
| Boyle WJ, Simonet WS, Lacey DL. | Osteoclast differentiation and activation. | Nature. 2003;423:337-342. | View PubMed Abstract | ||||
| Bucay N, Sarosi I, Dunstan CR, et al. | Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. | Genes Dev. 1998;12:1260-1268. | View PubMed Abstract | ||||
| Burgess TL, Qian Y, Kaufman S, et al. | The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. | J Cell Biol. 1999;145:527-538. | View PubMed Abstract | ||||
| Campagnuolo G, Bolon B, Feige U. | Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. | Arthritis Rheum. 2002;46:1926-1936. | View PubMed Abstract | ||||
| Campion, JM. | Osteoporosis in men. | Am Fam Physic. 2003;67:1521-1526. | View PubMed Abstract | ||||
| Capparelli C, Morony S, Warmington K, et al. | Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. | J Bone Min Res. 2003;18:852-858. | View PubMed Abstract | ||||
| Conde FA, Aronson WJ. | Risk factors for male osteoporosis. | Urol Oncol. 2003;21:380-383. | View PubMed Abstract | ||||
| Croucher PI, Shipman CM, Lippitt J, et al. | Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. | Blood. 2001;98:3534-3540. | View PubMed Abstract | ||||
| Eastell R. | Treatment of postmenopausal osteoporosis. | New Engl J Med. 1998;736-746. | View PubMed Abstract | ||||
| Eghbali-Fatourechi G, Khosla S, Sanyal A, et al. | Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. | J Clin Invest. 2003;111:1221-1230. | View PubMed Abstract | ||||
| Faruggia AN, Atkins GJ, To LB, et al. | Receptor activator of nuclear factor-KappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. | Cancer Res. 2003;63:5438-5445. | View PubMed Abstract | ||||
| Fata JE, et al. | The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. | Cell. 2000:103:41-50. | View PubMed Abstract | ||||
| Fidler IJ. | The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. | Nat Rev Cancer. 2003;3:453–458. | View PubMed Abstract | ||||
| Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. | TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. | J Exp Med. 1998;188:997-1001. | View PubMed Abstract | ||||
| Goss PE, Strasser K. | Aromatase inhibitors in the treatment and prevention of breast cancer. | J Clin Oncol. 2001;19:881-894. | View PubMed Abstract | ||||
| Grassi W, De Angelis R, Lamanna G, Cervini C. | The clinical features of rheumatoid arthritis. | Eur J Radiol. 1998:27(suppl 1):S18-S24. | View PubMed Abstract | ||||
| Hillner BE, Ingle JN, Chlebowski RT, et al. | American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. | J Clin Oncol. 2003;21:4042-4057. | View PubMed Abstract | ||||
| Hofbauer LC, Gori F, Riggs BL, et al. | Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. | Endocrinology. 1999;140:4382-4389. | View PubMed Abstract | ||||
| Hofbauer LC, Khosla S, Dunstan CR, et al. | Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. | Endocrinology. 1999;140:4367-4370. | View PubMed Abstract | ||||
| Hofbauer LC, Schoppet M. | Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. | JAMA. 2004;292:490-495. | View PubMed Abstract | ||||
| Honore P, Luger NM, Sabino MAC, et al. | Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. | Nat Med. 2000;6:521-528. | View PubMed Abstract | ||||
| Hsu H, et al. | Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. | Proc Natl Acad Sci. 1999:96:3540-3545. | View PubMed Abstract | ||||
| Ichinose Y, Tanaka H, Inoue N, Mochizuki S, Tsuda E, Seino Y. | Osteoclastogenesis inhibitory factor/osteoprotegerin reduced bone loss induced by mechanical unloading. | Calc Tissue Intl. 2004;75:338-343. | View PubMed Abstract | ||||
| Kessler B. | The natural history of prostate cancer. | Urol Clin North Am. 2003;30:219-226. | View PubMed Abstract | ||||
| Kitazawa S, Kitazawa R. | RANK ligand is a prerequisite for cancer-associated osteolytic lesions. | J Pathol. 2002;198:228-236. | View PubMed Abstract | ||||
| Kong YY, Yoshida H, Sarosi I, et al. | OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. | Nature. 1999;397:315-323. | View PubMed Abstract | ||||
| Kostenuik PJ, Capparelli C, Morony S, et al. | OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. | Endocrinology. 2001;142:4295-4304. | View PubMed Abstract | ||||
| Laan RF, van Riel PL, van de Putte LB, van Erning LJ, van’t Hof MA, Lemmens JA. | Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. | Ann Intern Med. 1993;119:963-968. | View PubMed Abstract | ||||
| Lacey DL, Tan HL, Lu J, et al. | Osteoprotegerin ligand modulates murine oseoclast survival in vitro and in vivo. | Am J Pathol. 2000;157:435-448. | View PubMed Abstract | ||||
| Lacey DL, Timms E, Tan HL, et al. | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. | Cell. 1998;93:165-176. | View PubMed Abstract | ||||
| Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I. | Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. | Lancet. 1992;340:1049-1052. | View PubMed Abstract | ||||
| Lindqvist E, Jonsson K, Saxne T, Eberhardt K. | Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. | Ann Rheum Dis. 2003;62:611-616. | View PubMed Abstract | ||||
| Luger NM, Honore P, Sabino MAC, et al. | Osteoprotegerin diminishes advanced bone cancer pain. | Cancer Res. 2001;61:4038-4047. | View PubMed Abstract | ||||
| Lukert BP, Raisz LG. | Glucocorticoid-induced osteoporosis: pathogenesis and management. | Ann Intern Med. 1990;112:352-364. | View PubMed Abstract | ||||
| Maalouf NM, Shane E. | Osteoporosis after solid organ transplantation. | J Clin Endo Metab. 2005;90:2456-2465. | View PubMed Abstract | ||||
| Melton LJ III, Alothman KI, Khosla S, Achenbach SJ, Oberg AL, Zincke H. | Fracture risk following bilateral orchiectomy. | J Urol. 2003;169:1747-1750. | View PubMed Abstract | ||||
| Melton LJ III. | Epidemiology worldwide. | Endocrinology and Metabolism Clinics. Philadelphia, PA: W. B. Saunders Company; 2003;1-13. | View PubMed Abstract | ||||
| Mirza F. | Bone health and aging: implications for menopause. | Endocrinology and Metabolism Clinics. Philadelphia, PA: W. B. Saunders Company; 2004. | View PubMed Abstract | ||||
| Mizuno A, Amizuka N, Irie K, et al. | Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. | Biochem Biophys Res Commun. 1998;247:610-615. | View PubMed Abstract | ||||
| Mochizuki S, Fujise N, Higashio K, Tsuda E. | Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats. | J Bone Min Metab. 2002;20:14-20. | View PubMed Abstract | ||||
| Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. | Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. | Cancer Res. 2001;61:4432-4436. | View PubMed Abstract | ||||
| Mundy GR. | Metastasis to bone: causes, consequences and therapeutic opportunities. | Nat Rev Cancer. 2002;2:584-593. | View PubMed Abstract | ||||
| Nelson HD, Helfand M, Woolf SH, Allan JD. | Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. | Ann Intern Med. 2002;137:529-541. | View PubMed Abstract | ||||
| O’Brien EA, Williams JHH, Marshall MJ. | Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria. | Biochem Biophys Res Commun. 2000;274:281-290. | View PubMed Abstract | ||||
| Palmer SC, Strippoli GFM, McGregor DO. | Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. | Am J Kid Dis. 2005;45:638-649. | View PubMed Abstract | ||||
| Pearse RN, Sordillo EM, Yaccoby S, et al. | Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. | Proc Natl Acad Sci U.S.A.2001;98:11581-11586. | View PubMed Abstract | ||||
| Roodman GD. | Mechanisms of bone metastasis. | N Engl J Med. 2004;350:1655-1664. | View PubMed Abstract | ||||
| Ross AB, Bateman TA, Kostenuik PJ, et al. | The effects of osteoprotegerin on the mechanical properties of rat bone. | J Mater Sci Mater Med. 2001;12:583-588. | View PubMed Abstract | ||||
| Sanders JL, Chattopadhyay N, Kifor O, Yamaguchi T, Butters RR, Brown EM. | Extracellular calcium-sensing receptor expression and its potential role in regulating parathyroid hormone-related peptide secretion in human breast cancer cell lines. | Endocrinology. 2000;141:4357-4364. | View PubMed Abstract | ||||
| Sasaki N, Kusano E, Ando Y, Yano K, Tsuda E, Asano Y. | Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. | Nephrol Dial Transplant. 2001;16:479-482. | View PubMed Abstract | ||||
| Schett G, Redlich K, Hayer S, et al. | Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. | Arthritis Rheum. 2003;48:2042-2051. | View PubMed Abstract | ||||
| Sezer O, Heider U, Jakob C, Eucker J, Possinger K. | Human bone marrow myeloma cells express RANKL. | J Clin Oncol. 2002;20:353-354. | View PubMed Abstract | ||||
| Smith BB, Cosenza ME, Mancini A, et al. | A toxicity profile of osteoprotegerin in the cynomolgus monkey. | Intl J Toxicol. 2003;22:403-412. | View PubMed Abstract | ||||
| Smith MR, McGovern FJ, Zietman AL, et al. | Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. | N Engl J Med. 2001;345:948-955. | View PubMed Abstract | ||||
| Stoch SA, Parker RA, Chen L, et al. | Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. | J Clin Endocrinol Metab. 2001;86:2787-2791. | View PubMed Abstract | ||||
| Stolina M, et al. | RANKL is a marker and mediator of local and systemic bone loss. | J Bone Miner Res. 2005;20(10):1756-1765. | View PubMed Abstract | ||||
| Thomas RJ, Gulse TA, Yin JJ, et al. | Breast cancer cells interact with osteoblasts to support osteoclast formation. | Endocrinology. 1999;140:4451-4458. | View PubMed Abstract | ||||
| Vanderkerken K, De Leenheer ED, Shipman C, et al. | Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. | Cancer Research. 2003;63:287-289. | View PubMed Abstract | ||||
| Wehren L. | The epidemiology of osteoporosis and fractures in geriatric medicine. | Clin Geriatr Med. 2003;19:245-258. | View PubMed Abstract | ||||
| Yasuda H, Shima N, Nakagawa N, et al. | Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. | Proc Natl Acad Sci USA. 1998;95:3597-3602. | View PubMed Abstract | ||||
| Yuan YY, Lau AG, Kostenuik PJ, et al. | RANKL has detrimental effects on cortical and trabecular bone volume, mineralization, and bone strength in mice. | Poster presentation at Bone Quality 2005 meeting, held May 2-3, 2005, in Bethesda, MD. | View PubMed Abstract | ||||